262438-43-7
Product Name:
ATN-161
Formula:
C23H35N9O8S
Synonyms:
1-Acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-aspartamide;Ac-PHSCN-NH2;Ac-Pro-His-Ser-Cys-Asn-NH2, PHSCN (Modifications: Pro-1 = N-terminal Ac, Asn-5 = C-terminal amide)
Inquiry
COMPUTED DESCRIPTORS
| Molecular Weight | 597.6 g/mol |
|---|---|
| XLogP3 | -4.7 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 15 |
| Exact Mass | 597.23293028 g/mol |
| Monoisotopic Mass | 597.23293028 g/mol |
| Topological Polar Surface Area | 273 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 1020 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy. Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is expected to extend to a variety of cancers.